Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Appendix

Key Questions Reviewed by the Work Group and Member(s) Responsible for Literature Summary


Performance Characteristics

  • Does the sensitivity and specificity of available tests for C. trachomatis and N. gonorrhoeae vary with respect to anatomic site from which the specimen was collected and/or specimen type?
    • Joan Chow, DrPH, California Department of Public Health, Richmond, California
    • Katherine Whitaker, PhD, Food and Drug Administration, Rockville, Maryland
  • What recommendations should be made for the detection of C. trachomatis and N. gonorrhoeae infections of the genital tract, rectum, and throat?
    • Gary Budnick, MHS, Connecticut Department of Public Health Laboratory, Hartford, Connecticut
    • Steven Shapiro, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC
    • Rick Steece, PhD, Infertility Prevention Project Laboratory Consultant, Pierre, South Dakota
  • What test recommendations should be made for the diagnosis of suspected LGV infections (inguinal and rectal presentations)?
    • Lisa Steele, PhD, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

Screening Applications

  • What specimen types are optimal for of C. trachomatis and N. gonorrhoeae screening purposes?
    • Charlotte Gaydos, DrPH, Johns Hopkins University, Baltimore, Maryland
    • Sarah Guerry, MD, Los Angeles County Department of Health Services, Los Angeles, California
    • Barbara Van Der Pol, PhD, Indiana University School of Public Health, Bloomington, Indiana
  • What parameters should be considered when selecting a C. trachomatis and N. gonorrhoeae test for screening purposes?
    • George Dizikes, PhD, Illinois Department of Public Health, Chicago, Illinois
    • Robert E Johnson, MD, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC
    • Scott Zimmerman, DrPH, Erie County Public Health Laboratory, Buffalo, New York

Economic Considerations

  • What economic considerations might influence laboratory testing?
    • Thomas Gift, PhD, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

Laboratory Confirmation

  • What approaches, if any, can be used to derive a definitive laboratory confirmation of C. trachomatis and N. gonorrhoeae?
    • Yetunde Fakile, PhD, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC
    • Dennis Ferrero, MPH, Department of Biological Sciences, University of the Pacific, Stockton, California
    • Rick Steece, PhD, Infertility Prevention Project Laboratory Consultant, Pierre, South Dakota
    • Barbara Van Der Pol, PhD, Indiana University School of Public Health, Bloomington, Indiana

Work Group Members
As of January 2009


Chair:
John R. Papp, PhD, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, Atlanta, Georgia.

Presenters: Gary Budnick, MHS, Connecticut Department of Public Health Laboratory, Hartford, Connecticut; Joan Chow, DrPH, California Department of Public Health, Richmond, California; George Dizikes, PhD, Illinois Department of Public Health, Chicago, Illinois; Dennis Ferrero, MPH, Department of Biological Sciences, University of the Pacific, Stockton, California; Charlotte Gaydos, DrPH, Johns Hopkins University, Baltimore, Maryland; Sarah Guerry, MD, Los Angeles County Department of Health Services, Los Angeles, California; Rick Steece, PhD, Infertility Prevention Project Laboratory Consultant, Pierre, South Dakota; Barbara Van Der Pol, PhD, Indiana University School of Public Health, Bloomington, Indiana; Katherine Whitaker, PhD, Food and Drug Administration, Rockville, Maryland; Scott Zimmerman, DrPH, Erie County Public Health Laboratory, Buffalo, New York; Yetunde Fakile, PhD, Thomas Gift, PhD, Robert E Johnson, MD, Steven Shapiro, Lisa Steele, PhD, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, Atlanta, Georgia;

Consultants: Stefanie Akselrod, MS, Food and Drug Administration, Rockville, Maryland; James Beebe, PhD, San Luis Obispo County Health Agency, San Luis Obispo, California; Julius Schachter, PhD, University of California, San Francisco, California; Shari Shea, MPH, Association of Public Health Laboratories, Silver Spring, Maryland; Melissa Singer, MPH, Centers for Medicare and Medicaid Services, Baltimore, Maryland; Dean Willis, DrPH, Florida Department of Health (Retired), Jacksonville, Florida; Kimberly Workowski, MD, Lisa Steele, PhD, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC and Emory University, Atlanta, Georgia; Kelly Wroblewski, MPH, Association of Public Health Laboratories, Silver Spring, Maryland.

 
Contact Us:
  • Centers for Disease Control and Prevention
    1600 Clifton Rd
    Atlanta, GA 30329-4027
  • 800-CDC-INFO
    (800-232-4636)
    TTY: (888) 232-6348
  • Contact CDC–INFO
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC-INFO